Cargando…

What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study

OBJECTIVES: To assess the impact of both the Committee on Safety of Medicines (CSM) warning (December 2003) and the National Institute for Health and Care Excellence (NICE) guidance (September 2005) on antidepressant prescription rates in children and adolescents within the UK primary care service....

Descripción completa

Detalles Bibliográficos
Autores principales: Tiffin, Paul A, Mediavilla, Jose L, Close, Helen, Kasim, Adetayo S, Welsh, Patrick, Paton, Lewis W, Mason, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686994/
https://www.ncbi.nlm.nih.gov/pubmed/31391190
http://dx.doi.org/10.1136/bmjopen-2018-028201
_version_ 1783442656696729600
author Tiffin, Paul A
Mediavilla, Jose L
Close, Helen
Kasim, Adetayo S
Welsh, Patrick
Paton, Lewis W
Mason, James M
author_facet Tiffin, Paul A
Mediavilla, Jose L
Close, Helen
Kasim, Adetayo S
Welsh, Patrick
Paton, Lewis W
Mason, James M
author_sort Tiffin, Paul A
collection PubMed
description OBJECTIVES: To assess the impact of both the Committee on Safety of Medicines (CSM) warning (December 2003) and the National Institute for Health and Care Excellence (NICE) guidance (September 2005) on antidepressant prescription rates in children and adolescents within the UK primary care service. SETTING: Population based study of primary care antidepressant prescribing using the Clinical Practice Research Datalink (CPRD). PARTICIPANTS: Under-18s presenting to primary care with a depressive disorder or related diagnostic code recorded in the CPRD. PRIMARY OUTCOME MEASURE: Antidepressant prescription rates per month per 100 000 depressed 4–17 year olds. RESULTS: Following the CSM warning, the prior trend towards increased prescribing rates for selective serotonin reuptake inhibitors (SSRIs) in children was significantly reversed (β for change in trend −12.34 (95% CI −18.67 to −6.00, p<0.001)). However, after the publication of the NICE guidelines the prior trend towards increased prescribing resumed for those SSRIs mentioned as potential treatments in the guidance (fluoxetine, citalopram and sertraline) (β for change in trend 11.52 (95% CI 5.32 to 17.73, p<0.001)). Prescribing of other SSRIs and tricyclics remained low. CONCLUSIONS: Despite a strong emphasis on psychosocial interventions for child and adolescent depression, it may be that the NICE guidelines inadvertently encouraged further antidepressant prescribing, at least for those SSRIs cited. Although the guidelines gave cautions and caveats for the use of antidepressants, practitioners may have interpreted these recommendations as endorsing their use in young people with depression and related conditions. However, more accurate prevalence trend estimates for depression in this age group, and information on the use of psychosocial interventions would be needed to rule out other reasons underlying this increase in prescribing.
format Online
Article
Text
id pubmed-6686994
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-66869942019-08-23 What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study Tiffin, Paul A Mediavilla, Jose L Close, Helen Kasim, Adetayo S Welsh, Patrick Paton, Lewis W Mason, James M BMJ Open Pharmacology and Therapeutics OBJECTIVES: To assess the impact of both the Committee on Safety of Medicines (CSM) warning (December 2003) and the National Institute for Health and Care Excellence (NICE) guidance (September 2005) on antidepressant prescription rates in children and adolescents within the UK primary care service. SETTING: Population based study of primary care antidepressant prescribing using the Clinical Practice Research Datalink (CPRD). PARTICIPANTS: Under-18s presenting to primary care with a depressive disorder or related diagnostic code recorded in the CPRD. PRIMARY OUTCOME MEASURE: Antidepressant prescription rates per month per 100 000 depressed 4–17 year olds. RESULTS: Following the CSM warning, the prior trend towards increased prescribing rates for selective serotonin reuptake inhibitors (SSRIs) in children was significantly reversed (β for change in trend −12.34 (95% CI −18.67 to −6.00, p<0.001)). However, after the publication of the NICE guidelines the prior trend towards increased prescribing resumed for those SSRIs mentioned as potential treatments in the guidance (fluoxetine, citalopram and sertraline) (β for change in trend 11.52 (95% CI 5.32 to 17.73, p<0.001)). Prescribing of other SSRIs and tricyclics remained low. CONCLUSIONS: Despite a strong emphasis on psychosocial interventions for child and adolescent depression, it may be that the NICE guidelines inadvertently encouraged further antidepressant prescribing, at least for those SSRIs cited. Although the guidelines gave cautions and caveats for the use of antidepressants, practitioners may have interpreted these recommendations as endorsing their use in young people with depression and related conditions. However, more accurate prevalence trend estimates for depression in this age group, and information on the use of psychosocial interventions would be needed to rule out other reasons underlying this increase in prescribing. BMJ Publishing Group 2019-08-07 /pmc/articles/PMC6686994/ /pubmed/31391190 http://dx.doi.org/10.1136/bmjopen-2018-028201 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Pharmacology and Therapeutics
Tiffin, Paul A
Mediavilla, Jose L
Close, Helen
Kasim, Adetayo S
Welsh, Patrick
Paton, Lewis W
Mason, James M
What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
title What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
title_full What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
title_fullStr What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
title_full_unstemmed What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
title_short What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
title_sort what were the impacts of the committee on safety of medicines warning and publication of the nice guidelines on trends in child and adolescent antidepressant prescribing in primary care? a population based study
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686994/
https://www.ncbi.nlm.nih.gov/pubmed/31391190
http://dx.doi.org/10.1136/bmjopen-2018-028201
work_keys_str_mv AT tiffinpaula whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy
AT mediavillajosel whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy
AT closehelen whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy
AT kasimadetayos whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy
AT welshpatrick whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy
AT patonlewisw whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy
AT masonjamesm whatweretheimpactsofthecommitteeonsafetyofmedicineswarningandpublicationoftheniceguidelinesontrendsinchildandadolescentantidepressantprescribinginprimarycareapopulationbasedstudy